Oragenics, Inc.
OGEN
$0.86
$0.000.40%
AMEX
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -100.00% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -100.00% |
| Cost of Revenue | -74.89% | -75.07% | -73.81% | -73.44% | 130.20% |
| Gross Profit | 74.89% | 75.06% | 73.77% | 73.37% | -131.69% |
| SG&A Expenses | 4.98% | -1.36% | 5.55% | 18.20% | 41.95% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -48.90% | -51.52% | -50.56% | -49.58% | 91.47% |
| Operating Income | 48.90% | 51.50% | 50.51% | 49.49% | -92.16% |
| Income Before Tax | 45.38% | 47.22% | 49.00% | 48.84% | -96.79% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 45.38% | 47.22% | 49.00% | 48.84% | -96.79% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 45.38% | 47.22% | 49.00% | 48.84% | -96.79% |
| EBIT | 48.90% | 51.50% | 50.51% | 49.49% | -92.16% |
| EBITDA | 83.24% | 70.57% | 60.47% | 49.56% | -92.71% |
| EPS Basic | 91.22% | 87.35% | 83.86% | 78.51% | -36.10% |
| Normalized Basic EPS | 91.22% | 87.35% | 83.86% | 78.51% | -36.10% |
| EPS Diluted | 91.22% | 87.35% | 83.86% | 78.51% | -36.10% |
| Normalized Diluted EPS | 91.22% | 87.35% | 83.86% | 78.51% | -36.10% |
| Average Basic Shares Outstanding | 477.00% | 351.93% | 293.61% | 194.59% | 99.16% |
| Average Diluted Shares Outstanding | 477.00% | 351.93% | 293.61% | 194.59% | 99.16% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |